Michael J. Pishvaian - Lombardi Comprehensive Cancer Center, Georgetown University

基本信息

浏览量：182

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 318 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Clinical Outcomes of Liposomal Irinotecan in Patients with Advanced Pancreatic Cancer Previously Treated with Conventional Irinotecan: A Meta-Analysis of Real-World Evidence

Amol Gupta,Ana De Jesus-Acosta,Dung Le,Michael Pishvaian,Neeha Zaidi,Lei Zheng,Daniel Laheru

CANCER (2024)

引用0浏览0WOS引用

Brightline-2: a Phase IIa/IIb Trial of Brigimadlin (BI 907828) in Advanced Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma or Other Solid Tumors

Changhoon Yoo,Angela Lamarca,Hye Jin Choi,Arndt Vogel,Michael J Pishvaian,Lipika Goyal,Makoto Ueno,Angela Märten,Michael Teufel, Lijiang Geng,Chigusa Morizane

Future oncology (London, England)no. 16 (2024): 1069-1077

引用0浏览0WOS引用

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Michael Smith,Aung Naing,Todd Bauer,Kyriakos P Papadopoulos,Osama Rahma,Elena Garralda,Glenn J Hanna,Michael J Pishvaian, Xuejun Chen,Sven Gogov,Omar Saavedra,Howard Kallender,LuLu Cheng, Emil Kuriakose

BMJ Oncologyno. 1 (2024)

引用0浏览0引用

A Phase 1b Study of the OxPhos Inhibitor ME-344 in Combination with Bevacizumab in Refractory Metastatic Colorectal Cancer

Patrick M. Boland,Heinz-Josef Lenz,Mike Cusnir,Vaia Florou,Michael J. Pishvaian,Deirdre J. Cohen,Kristen Keon Ciombor,Arthur Winer,Jessie Yanxiang Guo,Sandra Algaze, Sandra E. Wiley, Richard Ghalie,Howard S. Hochster

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): TPS222-TPS222

引用0浏览0引用

Association Between TP53 Gain of Function and Loss of Function Mutational Subgroups and Survival in Pancreatic Adenocarcinoma

Nitzan Zohar,Edik Matthew Blais,Adam Mueller,Dzung Thach, Patricia Miren de Arbeloa,Lynn McCormick Matrisian,Emanuel Petricoin,Michael J. Pishvaian,Andrew Eugene Hendifar,Atrayee Basu Mallick,Harish Lavu,Charles J. Yeo,Babar Bashir,Avinoam Nevler

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 694-694

引用0浏览0引用

Abstract A080: an Analysis of Outcomes in Patients (pts) with Advanced Pancreatic Cancer (PDAC) Whose Tumors Harbor Pathogenic BRCA1 or BRCA2 Mutations Based on Gene Mutation Location

Jamie Hur,Thomas McPhaul,Dea Cunningham,Lei Zheng, Christopher J Pishvaian,Daniel Laheru,Ana De Jesus-Acosta,Dung Le,Neeha Zaidi,Nilo Azad,Ilene Browner,William R Burns,Richard Burkhart,Kelly Lafaro,Amol Narang,Jin He,Valerie Lee,Jonathan R Brody,Michael J Pishvaian

Cancer Researchno. 17_Supplement_2 (2024)

引用0浏览0引用

A Phase 2 Study Evaluating Response and Biomarkers in Patients with Microsatellite Stable (MSS) Advanced Colorectal Cancer (CRC) Treated with Nivolumab/relatlimab

Eric Christenson,Jennifer N. Durham,Madelena Brancati, Heather Davis Bruning, Susan Petrie,Hao Wang,Jiayun Lu,Katherine M. Bever,Dan Laheru,Ana De Jesus-Acosta,Ross C. Donehower,Michael J. Pishvaian,Nilofer Saba Azad,Qingfeng Zhu,Nicolas Jose Llosa,Franck Housseau,Robert Anders,Drew M. Pardoll,Dung T. Le

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Outcomes in Patients with Pancreatic and Ampullary Cancer Whose Tumors Harbor Pathogenic APC Mutations

Christopher Pishvaian,Thomas Mcphaul,Dea Cunningham,Lei Zheng,Dan Laheru,Ana De Jesus-Acosta,Dung T. Le,Ilene S. Browner,William Burns,Richard Burkhart,Kelly Lafaro,Amol Narang,Jin He,Valerie Lee,Michael J. Pishvaian

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 693-693

引用0浏览0引用

Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

Michael Cerniglia,Joanne Xiu,Axel Grothey,Michael J. Pishvaian,Yasmine Baca, Jimmy J. Hwang,John L. Marshall,Ari M. Vanderwalde,Anthony F. Shields,Heinz‐Josef Lenz,W. Michael Korn,Mohamed E. Salem, Philip A. Philip,Richard M. Goldberg, Jia Zeng,Sunnie S. Kim

openalex

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn